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Since the original implication ofclass I molecules of the MHC in CTL recogni-
tion ofvirus-infected cells (1), significant advances have been made in our under-
standing ofsuch recognition ofviral antigens. CTL recognition originally was as-
sumedto involverecognitionofsurface viral glycoproteins on infected cells. However
while anti-MHC mAbs inhibitedrecognition by CTL, anti-virus glycoprotein anti-
bodies did not (2). Also, CTL for a polymorphic virus such as influenza A usually
reacted with all influenza virus strains that have differing glycoproteins on the sur-
face (3, 4).
For rare murine T cell clones that distinguished between influenza virus strains,
it was possible to map specificity to virus polymerase or nucleoprotein (NP)l (5,
6). The latter was confirmed by transfection and NP was shown to be a target an-
tigen for themajority population ofmurine CTL thatcrossreactwithdifferentvirus
subtypes (7, 8). Epitopes were localized by transfecting fragments ofNP into target
cells (9), and when appropriate peptides were synthesised, they were recognized by
CTL (10).
Similar studieswere carriedoutin man. Usinga set ofrecombinant vacciniaviruses
to expresseach viral protein in appropriate target cells, humanpolyclonal CTL were
shown to recognize the conserved internal proteins ofinfluenza A virus: NP, basic
polymerase (PB2), andthe matrix protein (Ml) (11). Further, peptides were identified
that were derived from the influenza NP and matrix protein and were recognized
by virus-specific human CTL in association with HLA-B37 and HLA-A2, respec-
tively (10, 12). Thus results in mouse and man showed that viral proteins are recog-
nized as peptide fragmentsthatprobablybind specifically toclassIMHC molecules.
To elucidate the nature of the tripartite interaction between virus, MHC mole-
cule, and TCR, further experiments have been performed where HLA-A2 was the
restricting element. The three-dimensional structure ofthis molecule (13, 14), re-
vealed a groove on its surface between two long a helices (al and a2) lying across
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an eight-stranded 0-pleated sheet. An unidentified electron density, probably a mix-
ture of peptides, was seen in the groove (13, 14).
Experiments with naturally occurring variants of HLA-A2 and deliberately con-
structed mutants of HLA-A2 containing single amino acid changes (15) have identified
residues within the groove ofthe HLA-A2 molecule that may be important for binding
the influenza matrix peptide. However, the results also showed that the viral peptide
must interact with the MHC molecule with some flexibility (16).
To determine the way in which this matrix peptide fits into the proposed antigen-
binding site of HLA-A2, a series of peptide analogues, each containing a point mu-
tation, was synthesized. Each was assayed for its ability to sensitize target cells and
to compete with the natural sequence for recognition by CTL. These experiments
could distinguish between the residues necessary for recognition by the antigen receptor
of the T cell and those needed to bind to the restriction element.
Materials and Methods
Peptides.
￿
The index or native matrix peptide 57-68 (sequence: lys, gly, ile, leu, gly, phe,
val, phe, thr, leu, thr, val), a series ofanalogue peptides with single amino acid substitutions
within the sequence and a set of shortened peptides, were synthesized by solid phase tech-
niques on a peptide synthesiser (model 430A; Applied Biosystems, Inc., Foster City, CA).
Commercially available amino acid phenylacetamidomethyl resins and t-Boc-suitably pro-
tected amino acids were used. All couplings were performed usinga 2 .5-mol excess of t-Boc-
amino acid and dicyclohexyl-carbodiimide over the number ofmilliequivalents ofamino acid
on the resin. The peptides were deprotected and removed from the resin simultaneously by
treatment with anhydrous hydrogen fluoride in the presence of anisole, dimethyl sulphide,
and indole. The peptides were separated from the various organic side products by extraction
with ether and isolated from the resinby extraction with 517c acetic acid and subsequent lyophyli-
zation. The purity of the crude product was determined by HPLC on a C-18 reverse-phase
column. All of the peptides contained >90% of the desired product.
Blood Donor.
￿
JM was a healthy male member oflaboratory staffand was HLA typed by
standard techniques by Dr. A. Ting and associates, Nuffield Department of Surgery, Oxford.
His tissue type was HLA A2 ; B15; B51; C3; DR4. In this report all cells used carried the
common type of HLA-A2, also known as HLA-A2.1.
CTL Lines.
￿
CTL lines were prepared from influenza A virus-stimulated cells from the
HLA-A2' donorJM, prepared as described previously (17). The cells were restimulated once
a week with equal numbers of irradiated (3,000 rad) autologous lymphoblastoid cells that
had been pretreated with matrix peptide 57-68 (60 pM for 1 h), and rIL-2 (Cetus Corp.,
Emeryville, CA) at 10 U/ml. Cells were also fed twice weekly with medium containing 10
U/ml rIL-2. CTL lines have been maintained for >12 wk and were highly specific for HLA-
A2 matrix peptide 57-68.
CTL Clones.
￿
CTL clones were prepared as has been previously described (16). Briefly,
cells from aJM CTL line established for 14 d were plated by limiting dilution onto autolo-
gous peptide-pulsed irradiated feeder cells, 104 well, in U-bottomed 96-well microtitre trays
in medium containing rIL-2 to 10 U/ml. 8:48 wells seeded at 10 cells/well, and 5:36 wells
seeded at 1 cell/well showed growth after 2-3 wk. They maintained their growth for 6-8
wk. Clones had individual fine specificities, shown here and previously (16), that were con-
stant throughout their life . They are referred to as `clones' because they grew out at low fre-
quency, but more formal proof of monoclonality of each has not yet been obtained.
Target Cells.
￿
EBVtransformed B lymphoblastoid cell lines were prepared as described
previously (18) for use as target cells. These were labeled with "Cr (Amersham International,
Amersham, UK) before use in lytic assays.
The LyticAssay.
￿
This was performed asdescribed previously (4). CTL were used as effector
cells by mixing with 104 5'Cr-labeled target cells at different ratios. Peptides were added to
a final concentration of 0.01-10 uM in the assay. Supernatants were harvested after 5 h andspecific lysis was calculated from the formula: 100x (E-M/D- M), where E, experimental
release; M, release in presence ofculture medium; D, release in presence of5% Triton X-100.
Competition between Peptides.
￿
Blocking assays were performed by adding the native matrix
peptide 57-68at concentrations from 0.01 to 10 pM, together with an analogue peptide that
was not recognized by CTL, in the lyticassay. The analogue or `blocking'peptide was used
at a finalconcentration of300 pM. Conditions for optimal blocking were defined before these
experiments and were identical to those described by Bodmer et al. (19).
Blocking at the Level ofthe Target Cell.
￿
S1Cr-labeled target cells were preincubated with com-
petitor peptides at 300 gM with or without the index peptide 57-68 at concentrations from
0.1 to 10 pM. Preincubation was at 37°C for 1 h, after which time target cellswere washed
three times before use in the cytolytic assay.
Results
Determination oftheOptimalLength ofMatrix PeptideRecognized by Influenza-specific CTL
LinesandClones. Comparisons were made ofrecognition by a matrix peptide-specific
polyclonal CTL line of the matrix peptides 57-68 or 56-68 and four other peptides,
58-68, 59-68, 60-68, and 56-67 . As shownin Fig. 1 A, peptides 57-68, 58-68, and
59-68 were seen in an almost identical fashion, whereas peptide 60-68 required 100-
fold higher concentration for equivalent lysis. Fig. 1 B shows that peptide 56-67
was also seen 100-fold less well than peptide 56-68. Thus, the amino acids at posi-
tion 59 (isoleucine) and 68 (valine) were shown to be important for recognition; the
shortest optimal peptide was 59-68. Similar experiments using three clones, K6,
K2, and D10, derived from the JM CTL line, showed (Fig. 2, A-C) that there were
fine differences in specificity between the clones, most notably in recognition of the
9 amino acid peptide 60-68 that was only recognized by CTL clone K2. However,
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FIGURE 1.
￿
(A)CTLrecognition ofau-
tologous B lymphocytes in the presence
of matrix peptides 57-68, 58-68,
59-68, and 60-68 atthe concentrations
shown. The killer/target ratio was 5:1 .
(B) CTL recognition of autologous B
lymphocytes in the presence ofthe ma-
trix peptides 56-68 and 56-67 at the
concentrations shown. The killer/target
ratio was 5:1 . Residue 56 is thr.2048
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￿
Clonal differences in rec-
ognition of matrix peptides 57-68,
58-68, 59-68, and60-68. Clones K6,
K2, and D10 derived from JM CTL
line were tested forrecognition of au-
tologous Blymphocytes in thepresence
of the peptides at the concentrations
shown. Thekiller/target rat
in each case.
even though the polyclonal line comprised a numberoffine speciftcities, there was
amajor common features specific recognition ofthe matrix peptide with HLA A2.
Identification ofCriticalResiduesfor TCellRecognition.
￿
To approach thephysical and
chemical requirements for peptide recognition by T cell clones and binding to the
HLA-A2 molecule ofthe target cell, an analysiswas made ofrecognition ofpeptideRecognition of Alanine Substituted
Peptides
uM Peptide
analogues by a polyclonal CTL line and four CTL clones, D10, K2, K6, and 01.
The analogue peptides each had a single aminoacid substitution at aposition within
the sequence. Each peptide was titrated at concentrations from 0.01 to 10 PM and
an example ofthe full data is shown for the individual alanine substitutions in Fig.
3. Each peptide was incubated in the lytic assay with theJM CTL line and HLA-
A2-matched lymphoblastoid target cells. Alanine substitution at different positions
haddramatically different effectson recognition. An alanine substitution atposition
59 (I-A)had no effect on recognition. Substitutions ofalanineatpositions62 (F-A),
66 (L-'A), 60 (L-'A), 64 (F-A), 65 (T-A), and 63 (V-A) decreased recognition,
and a substitution at position 61, a conservative substitution ofalanine for glycine,
completely abrogated recognition.
The results summarised in Fig. 4 are from experimentswhere all ofthe analogue
peptides were tested. Because theyinclude data from three experiments, results are
shownin eachcase asapercentage ofthe lysisobtainedwith the native 57-68matrix
peptide. Individual substitutions at each position are ranked at the top ofthe figure
inthe same order as they appear vertically on the bar chart. Each peptidewas tested
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FIGURE 3.
￿
Recognition of al-
anine substituted peptides (56-
68M) at the concentrations
shown by JM CTL line with
FM (matched through HLA
A2) B lymphoblastoid target
cells. Thekiller/target ratiowas
5:1 .
FIGURE 4.
￿
JM CTL recognition of au-
tologous Blymphocytes in the presence of
54 analogue peptides with single amino
acid substitutionsindicated. Peptides were
used at 10 liM final concentration in the
assay. Thekiller/target ratiowas5:1 . Lysis
is givenas apercentageofspecific lysiswith
the 57-68index matrix peptide (M) (45-
60%). No peptide present (O).
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at a range ofconcentrations from 0.01 to 10 pM, but for clarity, only the 10-uM
result is shown. It was found that a greater latitude was possible for substitutions
at positions near the NH2 or COOH termini ofthe peptide compared with the cen-
tral positions. Therewasa core ofsix residues, 60-65, where few substitutions were
allowed. Recognitionofpeptide by theJMCTLlinerequired aglycine atposition61.
The fourCTL clones, D10, K2, K6, and 01, were assayed fortheir ability torecog-
nize the analogue peptides in order to determine whether there were differences in
specificity imposed by their different TCRs (Table I). In most cases the reactivity
of the clones reflected that of the line; for example, none of the clones were able
tolyse target cellsinthepresence ofsubstitutionsat position 61. Similarrecognition
was alsoapparent withsubstitutions atpositions 63, 67, and68. However, forseveral
substitutions at positions 59, 60, 62, 64, 65, and 66, different reactivity was seen
for individual clones. In each case where differential recognition was seen, at least
one clonewas capableoflysing target cells sensitized withthe peptide. Consequently,
the analogueswere capable ofbindingto theA2 molecule, and themostlikely expla-
nation for thedifferencesare sequence variations present in the TCRs oftheclones.
Inhibition of Recognition by JM CTL of the Native Matrix Peptide by Analogue Pep-
tides. Peptides containing aminoacid substitutionsthat were not recognized byJM
CTLline were used to compete with the native peptide in the lytic assay. Ifthe sub-
stituted peptides inhibitedorblocked recognition by CTL oftarget cells, these pep-
tidesmust bind to HLAA2, suggesting thatthesubstitutions that abrogaterecogni-
tion face the TCR.
Substitutions at positions 60 (L-'T), 64 (F-I), and 65 (T-K) resulted in pep-
tides that inhibited recognition (Fig. 5). Substitutions at positions 61, 62 (F-E),
and63 (V-For E), whichresulted inanalogue peptides not recognized by theCTL
line, did not block recognition of the native peptide. Therefore, we can model the
peptide with positions 60, 64, and 65 facing the TCR and positions 61, 62, and 63
interacting with the A2 molecule.
Blocking ofRecognition oftheNative Peptideby Competitor Peptides at theLevelofthe Target
Cell. Toconfirmthatthepreviousinhibition experiments reflected competition for
binding to HLA-A2 on the target cell rather than for the TCR, target cells were
preincubated with peptide analogues containing substitutions at positions 60, 61,
64, and65 together with thenative peptide. Afterwashing, thetargets were incubated
with the CTL in the lytic assay. Similar inhibition ofrecognition was seen (Fig. 6)
to that shown in Fig. 5, indicating that the peptides substituted at positions 60, 64,
and65, present in molarexcess compared withthe indexpeptide during preincuba-
tion, must bind to the target cell. Such results further support the hypothesis that
positions60, 64, and65 within the matrix peptide interact withthe antigen receptor
of the CTL.
Discussion
To understand themolecularbasis ofHLA restriction, we have attempted toiden-
tify the critical residues for binding the previously defined (12) influenza A virus
matrix peptide, 56-68, to HLA-A2. A necessary prerequisite to the identification
ofthe exact position ofthe peptide in the antigen-combining site is the determina-
tion of the conformation and orientation ofthe bound peptide. The strategy that
we have adopted was to assay the ability of peptide analogues, each containing aGOTCH ET AL.
TABLE I
Clonal Differences in Recognition of Substituted Peptides
Clones D10, K6, K2, and 01 derived from theJM CTL line were tested for
recognition of autologous B lymphoblastoid target cells in the presence of the
peptides indicatedat 10 WM final concentration in the assay. Comparisons were
made with recognition oftheindexmatrix peptide57-68andwere scored: + +,
lysis >90% of that with matrix peptide 57-68; +, lysis 50-90% of that with
matrix peptide 57-68; t , lysis 10-50% of that with matrix peptide 57-68; -
lysis <10% of that with matrix peptide 57-68. Theindex peptide 57-68 scored
+ + in all categories.
2051
Substituted
peptides
JM CTL
line D10
JM CTL
K2
Clones
K6 01
K59 + + + + +
F t + t + t
A ++ + ++ ++ -
Y t + t + -
E + + + + +
S60 + t + + + +
N + + - - ++
T t t - - ++
A61
S
T
L
V
D
E
K62 - - - - -
E
I
-
++
-
+
-
++
-
-
-
ND
V + + + - t
Y ++ ++ ++ - ND
D + - + - -
F63 - - - - -
Y
E - - - - t
R t - + _ -
N64 + t + - -
I t + + - +
S + + ++ + ++
Y t
-
f
-
t
-
-
-
t
-
K65 - - t -
G + t + + t
S66 + + + + + +
F + t ++ + -
R + t ++ t t
E + t t + t
D67 ++ ++ ++ + ++
A + + + + + + + + + +
K68 ++ ++ ++ ++ ++2052
￿
RECOGNITION OF MATRIX PEPTIDE ANALOGUES
70-
so .
50
40-
30 -
20 .
10
0 01
￿
1
￿
I
￿
10
UM "de
index .064
-~ Index
index
index . E62
-r-
index
Index . T60
a
f
a
x
70 .
60-
50-
30 .
,
y
50
e0
30
20-
.01
￿
1
￿
1
￿
10
uM Peptide
-~ index
index . F63
- ind.x .E63
index
-~- index .1361'
" ue,wrr Mws ~n Ki is,
~N "Ya2,NFN .
FIGURE 5.
￿
Blocking of CTL recognition of autologous B lymphocytes with the native matrix
peptide 57-68 by the analogue peptides indicated. The analogue peptides were notrecognized
byJM CTL. Theindexpeptide wasused at theconcentrations shown andthe analogue peptides
were at a final concentration of 300 gM.
pointsubstitution, either to act as targets forinfluenzaA virus matrix-specific CTL
lines or clones, or to inhibit recognition of the native sequence.
Theexperiments were carried outwith CTLlinesthat were originally stimulated
in vitro with influenza A virus and subsequently grown on matrix peptide 56-68-
pulsed autologous cells in the presence of IL-2. These lines were composed of at
least four clonal specificities, all directed at peptide plus HLA-A2. These could be
distinguished when individual clones were isolated when differences between them
were apparent (e.g., Fig. 2), although they shared specificity for matrix peptide and
HLA-A2. In experiments where recognition was completely abrogated, it is likely
that all component CTL clones were affected (see Table I).
A number of characteristics can be identified from the analysis ofT cell recogni-
tion of alarge number of analogue peptides. There are some positions, particularly
at the NH2 and COOH termini of the peptides that were permissive in their chem-
ical requirements. For example, the amino acid at position 68, normally a valine,
was shown to be necessary foroptimalactivity, butsubstitution with markedly differenta
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FIGURE 6.
￿
Blocking of recog-
nition of the indexmatrix pep-
tide 57-68 by competitor pep-
tides(K65, Y64, andN60) is at
thelevelofthetarget cell. CTL
recognition of autologous B
lymphocytes preincubated with
indexpeptide at concentrations
shownandthecompetitor pep-
tides shown at 300 pM. The
killer/target ratio was 3:1 in
each of the two experiments
shown.
amino acids such as lysine and aspartic acid did not reduce recognition by CTL.
In contrast, other positions have strict requirements for a particular type of amino
acid. The most extreme example was glycine-61 where none of theothersevenamino
acids tested, including alanine, generated an analogue that was capable of being
recognized by CTL or of inhibiting recognition ofthenative sequence. Intermediate
requirements were apparent at some positions, such as 62, where abranched hydro-
phobic amino acid in place ofthenatural phenylalanine gave a functioningpeptide.
The sequence corresponding to residues 61-65 appeared to be the most critical for
recognition, because it was contained in the shortest peptides that were recognized
and at least one substitution in each position resulted in complete loss of recogni-
tion. A central core ofcritical residues has been identified in other helper and cyto-
toxicT cell epitopes suggesting that the ends of these determinants have less confor-
mational constraints.
To distinguish thoseamino acids in thenative peptides that interact with HLA-A2
from those that aredirectly recognized by the TCR, analogues that could not sensi-
tize target cells were used in competitive inhibition assays with the native peptide.2054
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The conditions necessary for these assays were found to be identical to those de-
scribed by others (19), particularlythat thecompetingpeptidemust be in largemolar
excess and that it must be added before, or at the same time as, the native peptide.
Peptides containing substitutions atpositions 60, 64, and 65 when incubated in the
presence ofthe native peptide, competed effectively, whereas those with changes at
residues61-63 did not inhibit. We argue that competitionoccurs at thelevel ofbinding
to HLA-A2 becausewhen target cells were incubatedwith native and analogue pep-
tide andthen washed before adding totheCTL, inhibition wasstill observed. There
was no evidence of nonspecific toxicity because background chromium release of
these targets was in the normal range, <25% ofdetergent release. These experiments
allow us to conclude that the peptides with substitutions at positions 60, 64, and
65 bind effectively toHLA-A2 and, becausethey are so similarto thenative peptide,
we suggestthattheyadopt a similarconformation and position inthe peptide-binding
groove. The loss ofCTL recognition ofthese peptides would then be due to failure
ofinteractionwith theTCR. This is explained most simply ifthe substituted amino
acids point directly at the TCR. However, we cannot completely exclude the possi-
bility that one or more ofthese residues could point into the groove and affect the
fine positioning ofthe peptide, much as a mutation at position 9 in HLA-A2 does
(16). We consider this unlikely because these substitutions at residues 60, 64, and
65 abrogated recognition by allJM CTLlines and clones, unlike the HLA-A2 posi-
tion 9 mutation (16). The analogue peptides, with substitutions at positions 61-63,
which did not compete, identify residues that interact with HLA-A2.
A second approach to theidentification ofthe residuesthatpointtowards theTCR
was to analyze recognitionby CTL clones (Table I)(20). It was foundthatparticular
substitutions atpositions 59, 60, 62, 64, 65, and 66gave disparate results withdifferent
T cellclones; in eachcase thesewas at least oneanalogue that wasrecognized strongly
by one T cellcloneand notby another. Thesimplest interpretation ofthesefindings
is to orientate all ofthese positions towards the TCR. This would agree with our
interpretation ofthe competition experiments for positions 60, 64, and 65, but not
for position 62. One possible explanation is that the peptide can bind to HLA-A2
in two or more completely different ways. We consider this unlikely because there
appear to be relatively few epitopes in the 10 proteins ofinfluenza virus that are
recognized by CTL; only the matrix protein and a single epitope in that molecule
interact with HLA-A2 to be recognized by CTL (11). Thus, it is unlikely that this
matrix peptidewould contain more than one HLA-A2-associated epitope. A second
possibility is that position 62 points towards HLA-A2 and that the substitutions of
isoleucine, aspartic acid, ortyrosineforthenaturalphenylalanine affect thefine posi-
tioning ofthepeptide, orhave aneffect on theconformation ofHLA-A2, andthereby
abrogate recognitionbyclone K6but notbythe otherclones. This wouldbe analo-
gous to our finding that a mutation at position 9 ofHLA-A2, which is in the floor
of the groove, affected recognition of the matrix peptide by T cell clones K2 and
01 and not by the others (16); because it is unlikely that the TCRwould reach posi-
tion 9, this result is best explained by an effect on fine positioning ofthe peptide.
A similarexplanationforthe resultswiththe peptide substituted atposition62 allows
us to give equal weight to both types ofexperiment, competition, and differential
recognition by T cell clones.
One striking feature ofthe data is the permissiveness ofpeptide interaction withHLA-A2. The latter must bind to any of the analogues that stimulates one or more
T cell clones. Also, variant peptides that abrogate all response but compete, must
bind. Thus, ofall the analogue peptides tested, only 13 failed to bind andthesewere
all substituted at positions 61-63. This also suggests that these three positions must
make critical contact with HLA-A2.
The pattern that emerges, therefore, is that residues 61, 63, and probably 62 in-
teract with HLA-A2 and59, 60, 64, 65, and66 interact with theTCR. This is reminis-
cent of the analysis made of the interactions between an OVA peptide and IAd by
Sette et al. (21). There is no simple secondary structure of extended chain, turn,
or a helixthat satisfactorily meets all of these conditions and, as previously argued,
makes contact with residues 9, 66, 70, 152, and 156 in HLA-A2 (16). However, most
of these points would be met with thepeptide in an a helix as shown in Fig. 7. This
could fit into the groove in parallel with the two a helices of HLA-A2 and could
reach each of the above positions in that molecule. The two bulky phenylalanines
at positions 62 and 64 would point into and out of the groove, respectively, and the
essential glycine at position 61 would face one side, so meetingthe steric constraint
of a narrow groove (13, 14). Theglycine might face oneof the bulky residues at posi-
tions 66 (lysine), 70 (histidine), or 74 (histidine) of HLA-A2, allof which point into
the groove. Residues 61-63 would interact with the three sides of the groove and
60 and 64 would face the TCR. Other conditions imposed by the data are more
difficult to satisfy, however, and weaken the model. In the helical wheel shown in
Fig. 7, residue 65 points into the groove, but a substitution of lysine for threonine
abrogated recognition and competed; it is possible that the size and polarity ofthis
residue would enable its side chain to point out of the groove and interfere with
T cell recognition while still binding. Residues 59 and 66 both point deep into the
groove in this model but certain substitutions affected some CTL clones and not
others. It is possible that these affect orientation or conformation as argued for the
isoleucine at position 62 and the mutation in position 9 of HLA A2 (16). These spe-
cial argumentsweaken the model but do not preclude it, and at present, this seems
to be the best workinghypothesis. The proposal should lead to testable predictions,
particularly that proline substitutions mightdestroythehelix and, therefore, binding;
that it should be possible to complement abrogative mutations of HLA-A2 and pep-
tide to give a positive response; and that the model should lead to successful predic-
tion of peptide epitopes from other viruses. These are currently being tested.
Ultimately, the position andorientation of this peptide in HLA-A2 will be solved
by cocrystallization of HLA-A2 with peptide and X ray diffraction studies. A solu-
V
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FIGURE 7.
￿
The influenza matrix peptide 57-68 in a helical form, shown
as a helical wheel. In this orientation residues 60 and 64 face the TCR
and residues 61-63 face the A2 molecule.2056
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tion will be needed to the problem being encountered of binding peptide to purified
HLA-A2 molecules. This may require an understanding of how peptide enters the
A2 molecule and whether it exchanges naturally. As it is unlikely that many different
peptide MHC molecule complexes will be cocrystallized, a correlation between crystal
structure data and functionaldata, ofthe type discussed here, will be essential. This
should enable other peptide MHC interactions to be explored by this functional
approach.
Summary
CTL specific for the influenza A virus matrix peptide 57-68 and restricted by
HLA-A2 were studied. Their ability to recognize a set of analogue peptides, each
of which differed from the natural peptide by a single amino acid, was analyzed.
This revealed a core of five amino acids, 61-65, where one or more changes com-
pletely abrogated recognition. The glycine at position 61 was the only residue where
no substitution was tolerated. Analogue peptides that did not induce CTL-mediated
lysis were tested as competitors with the natural peptide; those with substitutions
at positions 60, 64, and 65 inhibited, identifying residues that interact with the TCR.
Another approach was to test a set of four CTL clones on all ofthe analogues. Marked
differences in recognition by individual CTL clones were observed for several sub-
stituted peptides. The data indicate that most of the analogues bind to HLA-A2
with possible differences in fine positioning of the peptide. An a helical orientation
for the peptide is discussed.
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Mark Saper for helpful discussions, and to Clare Crew for preparing the manuscript. We
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